Menu
Svensk version

BONESUPPORT HOLDING AB presents health economic evidence

Lund, Sweden, 19.00 CET, 18 September 2019 – BONESUPPORT HOLDING AB, listed on Nasdaq Stockholm - an emerging leader in orthobiologics for the management of bone voids announced today that health economic data was presented during the EBJIS conference entitled "The economic burden of osteomyelitis in the UK". Data shows that the number of patient visits after surgery and hospital time can be shortened using CERAMENT® G.

The analysis showed that single stage procedure with the addition of CERAMENT G or CERAMENT V at Nuffield Orthopaedic Hospital reduced patients stay in hospital by 35 percent or over six days less per patient, on average, in the treatment of osteomyelitis.

“Allowing patients to return home a week earlier is not only good for the hospital but more importantly it is better for patients.” said Emil Billbäck, CEO of BONESUPPORT™.

The data is based on an analysis of more than 25,000 patients in the UK who were surgically treated for chronic osteomyelitis during 2013-2017. The patients were followed two years before and two years after surgery. The aim of the analysis was to compare the clinical and financial results of Nuffield Orthopedic Hospital's care model including antibiotic eluting CERAMENT with the care provided at other hospitals in England.

The data was presented at the 38th EBJIS (EUROPEAN BONE AND JOINT INFECTIONS SOCIETY) conference September 12-13. The full analysis is expected to be published shortly.

About BONESUPPORT™

BONESUPPORT (Nasdaq Stockholm: BONEX) develops and commercializes innovative injectable bio-ceramic bone graft substitutes that remodel to the patient’s own bone and have the capability of eluting drugs. BONESUPPORT’s bone graft substitutes are based on the patented technology platform CERAMENT. The company is conducting several clinical studies to further demonstrate the clinical and health economic benefits its products deliver and a Premarket approval filing with the FDA (USA) for CERAMENT G is planned in 2021. The company is based in Lund, Sweden, and the net sales amounted to SEK 97 million in 2018. Please visit www.bonesupport.com for more information.

BONESUPPORT and CERAMENT are registered trademarks of BONESUPPORT AB.

For more information contact:

BONESUPPORT AB
Emil Billbäck, CEO
+46 (0) 46 286 53 70

Håkan Johansson, CFO
+46(0) 46 286 53 70
ir@bonesupport.com

Cord Communications
Charlotte Stjerngren
+46 (0)708 76 87 87
charlotte.stjerngren@cordcom.se
www.cordcom.se

Disclaimers:

EU Market Abuse Regulation

This information is such information as BONESUPPORT HOLDING AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 19.00 CET on 18 September 2019.

 

  

 

Downloads

Press release PDF (161.63 KB)

BONESUPPORT, Tue Sep 10, 2019

@BONESUPPORT_AB are proud to be Platinum sponsor again for @EBJIS 2019, starts Thursday 12th September in Antwerp. https://t.co/z6XXYBsipT

BONESUPPORT, Fri Aug 2, 2019

@MSIS 2019 CERAMENT Bone Void Filler injectable bone graft substitute remodels to bone 6-12 months. Meet… https://t.co/vbLgu854rt

BONESUPPORT, Fri Aug 2, 2019

@BONESUPPORT_AB is exhibiting at the MSIS congress NYC. Hear more about CERAMENT G resorbable injectable antibiotic… https://t.co/JJ8wURMyNT

BONESUPPORT, Thu Mar 21, 2019

Busy first day at @OBIC! Come a meet BONESUPPORT tomorrow and learn more about CERAMENT G and V. https://t.co/Ulc3BGPgIF